A comprehensive five-year study has unveiled that a low-carbohydrate diet, combined with continuous remote care, can enable individuals with type 2 diabetes (T2D) to achieve sustainable remission while significantly cutting down their reliance on diabetes medications.
The research, published in Diabetes Research and Clinical Practice, assessed a telemedicine initiative designed to support T2D patients in adopting a very low-carbohydrate diet aimed at reaching nutritional ketosis. The results indicated a high retention rate among participants, resulting in notable health improvements over the five years, including weight loss, enhanced levels of HDL cholesterol (up by 17.4%), reduced triglycerides (down by 18.4%), and decreased inflammation markers, including a striking 43.6% reduction in high-sensitivity C-reactive protein (hs-CRP). These changes contributed to improved cardiometabolic health and instances of diabetes remission.
Background on Medication Reduction
The study found that over 46% of diabetes medication adjustments resulted in complete eliminations, with nearly 60% when excluding metformin. This significant decrease highlights the potential for new therapies to reverse T2D—a condition traditionally viewed as progressive and chronic. Successful interventions can lower glycated hemoglobin (HbA1c) levels and diminish the need for glucose-lowering medications, paving the way for long-lasting, medication-free remission. This is defined as maintaining HbA1c levels below 6.5% for three consecutive months without the use of glucose-lowering drugs.
Achieving remission carries considerable long-term health advantages, as prolonged hyperglycemia can elevate the risk of various diabetes-related complications. Effective strategies to attain remission encompass insulin therapy, surgical interventions, and nutritional therapies with significant restrictions on carbohydrates or caloric intake.
Study Design and Methodology
This investigation aimed to evaluate the long-term impacts of a telemedicine program on diabetes status, blood sugar management, weight, medication use, and overall cardiometabolic health. Participants included individuals with T2D and a body mass index (BMI) exceeding 25. Initially, they were enrolled in a two-year comparative study of continuous care interventions (CCI) versus usual care (UC). Following the initial two years, those in the CCI group were given an opportunity to continue for an additional three years.
Of the 194 individuals in the CCI group, 169 remained engaged throughout the study. The intervention, which occurred entirely online, utilized an app to facilitate nutrition counseling and diabetes medication management via telemedicine. Participants followed a strict carbohydrate intake of less than 30 grams per day to achieve and maintain nutritional ketosis. The app enabled users to monitor their weight, blood glucose levels, and beta-hydroxybutyrate (BHB) levels, while also providing access to health coaches, physicians, and a supportive community.
Medication adjustments were carefully managed, allowing metformin to be discontinued only if contraindicated or poorly tolerated. Data collection occurred at multiple intervals throughout the study, including the beginning, one year, two years, three-and-a-half years, and five years, focusing on inflammation markers, weight, and blood test results.
Statistical Analysis
A range of statistical models was utilized to analyze changes over the five-year duration. Linear mixed-effects models were applied to account for within-subject correlations over time, adjusting for variables such as age, sex, and duration of diabetes. Metrics including HbA1c, weight, fasting insulin, and cardiovascular markers were evaluated across five distinct time points to capture longitudinal trends. The findings were statistically significant, with adjusted p-values confirming substantial reductions in fasting insulin levels, inflammation markers, and lipid profiles, reinforcing the robustness and sustainability of the intervention’s benefits.
Comparison to Other Research
The remission rates observed in this study surpassed those reported in other notable lifestyle therapy trials. For instance, the Look AHEAD trial documented a 7.3% remission rate over four years, while the DiRECT trial noted a 13% remission rate at five years. In contrast, this study found that 20% of participants achieved remission at the five-year mark, with 32.5% attaining HbA1c levels below 6.5% without medication or relying solely on metformin. The heightened rate of sustained remission is likely attributable to the enduring carbohydrate restrictions and ongoing support from the healthcare team.
Conclusions
The findings of this study emphasize the efficacy of carbohydrate-restricted therapy coupled with continuous remote care in achieving and maintaining remission for T2D. With 20% of participants reaching remission after five years and 15 out of 24 maintaining their remission for four years, the outcomes reflect the intervention’s success. Furthermore, 32.5% of participants achieved reversal of their condition without the need for medications or only using metformin. Even those who did not reach remission exhibited stable blood sugar levels and a marked decrease in medication use.
The consistent reductions in HbA1c, fasting insulin levels, and inflammation markers underline the effectiveness of this approach in mitigating long-term health risks. Additionally, the notable decline in the burden of medication—evidenced by a 40% decrease in medication effect scores—further establishes the clinical value of the intervention.
The elements of remote care, peer support, access to healthcare professionals, and clinical success contributed to a high retention rate, with 47% of participants remaining engaged for the full five years while experiencing improvements in blood sugar levels, body weight, and cardiovascular health. Sustained enhancements in cardiovascular metrics and significant reductions in inflammatory markers over this period indicate a lower cardiovascular risk.
While diabetes management typically necessitates increased medication, this study revealed a reduced need for pharmacological intervention, with some participants achieving complete deprescription. The remission rates achieved herein surpassed those of other lifestyle therapy trials, reinforcing the study’s significance.
Despite its strengths, including a long duration and applicability to a broad population of individuals with T2D (not just those newly diagnosed), the study lacked a comparison group throughout the entire five years and featured limited racial diversity among participants.
Related topics:
Weight Loss Injections May Alleviate Alcohol Addiction
Electronic Nudges Increase Flu Vaccination Rates in Non-Diabetics but Not in Diabetics
Blood Vitamin E Levels Linked to Blood Pressure in Non-Diabetic Adults
